The most widely used anti-HER2 treatment was double blockade with Pertuzumab and Trastuzumab both as a neoadjuvant (71%) and adjuvant (58%) as well as in the first line of therapy of metastatic disease (100%). Here, ERBB2 is linked to metastatic neoplasm.